Skip to main content
. 2024 Feb 6;31(4):2632–2639. doi: 10.1245/s10434-023-14875-5

Table 2.

Pathological characteristics

Total N= 1152 PDAC N= 1047 I-IPMN N = 105 P value

Staging

 Ia/Ib

 IIa/IIb

 III

 IV

533 (46)

437 (38)

167 (14)

15 (1)

481 (46)

396 (38)

157 (15)

13 (1)

52 (50)

41 (39)

10 (10)

2 (2)

0.458

T stage

 Complete NAT response

 T 1 a,b,c

 T 2

 T 3

 T 4

65 (6)

269 (23)

482 (42)

308 (27)

28 (2)

64 (6)

232 (22)

450 (43)

273 (26)

28 (3)

1 (1)

37 (35)

32 (30)

35 (33)

0

< 0.001

N stage

 N 0

 N 1

 N 2

667 (58)

332 (29)

153 (13)

601 (57)

304 (29)

142 (14)

66 (63)

28 (27)

11 (10)

0.506
Metastatic at surgery 15 (1) 13 (1) 2 (2) 0.568
Harvested lymph nodes, mean ± SD 21.4 ± 9.9 21.5 ± 9.8 20.2 ± 10.8 0.190

Pathologic grade

 Undetermined

 G1

 G2

 G3

 G4

77 (7)

68 (6)

617 (54)

375 (33)

11 (1)

75 (7)

47 (4)

571 (55)

340 (32)

11 (1)

2 (2)

21 (20)

46 (44)

35 (33)

0

< 0.001

IPMN duct involvement

 Branch duct

 Main duct/Mixed

20 (19)

85 (81)

Perineural invasion 503 (44) 473 (45) 30 (29) 0.001
Lymphovascular invasion 176 (15) 165 (16) 11 (10) 0.151
R1 108 (9) 103 (10) 5 (5) 0.089

Bold values indicate statistically significant results (p < 0.05)

SD = standard deviation, NAT = neoadjuvant therapy, PDAC = pancreatic ductal adenocarcinoma, I-IPMN = invasive intraductal mucinous cystic neoplasm